Switch theme
Sign up to access all valuation multiples
Hikma Pharmaceuticals PLC is engaged in developing, manufacturing, and marketing a broad range of generic, branded and non-branded, in-licensed pharmaceutical products. The firm operates in three segments: injectables, generics, and branded. The majority of the revenue for the company is generated from its injectables segment under which it supplies hospitals across markets with generic injectable products, supported by its manufacturing facilities. Geographically, North America is the company's key revenue generating market followed by Middle East and North Africa, United Kingdom, Europe and the rest of the world.
2005
9.5K+
LTM Revenue $2.5B
LTM EBITDA $650M
$6.3B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Hikma Pharmaceuticals has a last 12-month revenue of $2.5B and a last 12-month EBITDA of $650M.
In the most recent fiscal year, Hikma Pharmaceuticals achieved revenue of $4.0B and an EBITDA of $936M.
Hikma Pharmaceuticals expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Hikma Pharmaceuticals valuation multiples based on analyst estimates| FY 2023 | FY 2024 | FY 2025 | LTM | NTM | |
|---|---|---|---|---|---|
| Revenue | $3.7B | $4.0B | XXX | XXX | XXX |
| Gross Profit | $1.6B | $1.8B | XXX | XXX | XXX |
| Gross Margin | 43% | 44% | XXX | XXX | XXX |
| EBITDA | $711M | $936M | XXX | XXX | XXX |
| EBITDA Margin | 19% | 23% | XXX | XXX | XXX |
| Net Profit | $242M | $245M | XXX | XXX | XXX |
| Net Margin | 7% | 6% | XXX | XXX | XXX |
| Net Debt | $1.2B | $1.2B | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of April 15, 2025, Hikma Pharmaceuticals's stock price is GBP 18 (or $24).
Hikma Pharmaceuticals has current market cap of GBP 4.0B (or $5.2B), and EV of GBP 4.9B (or $6.3B).
See Hikma Pharmaceuticals trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $6.3B | $5.2B | XXX | XXX | XXX | XXX | $2.25 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Sign UpAs of April 15, 2025, Hikma Pharmaceuticals has market cap of $5.2B and EV of $6.3B.
Hikma Pharmaceuticals's trades at 2.0x LTM EV/Revenue multiple, and 7.5x LTM EBITDA.
Analysts estimate Hikma Pharmaceuticals's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See valuation multiples for Hikma Pharmaceuticals and 10K+ public comps| FY 2024 | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|
| EV | $6.3B | XXX | XXX | XXX |
| EV/Revenue | 1.6x | XXX | XXX | XXX |
| EV/EBITDA | 6.7x | XXX | XXX | XXX |
| P/E | 11.2x | XXX | XXX | XXX |
| P/E/Growth | 2.8x | XXX | XXX | XXX |
| EV/FCF | 14.8x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Sign UpHikma Pharmaceuticals's NTM/LTM revenue growth is 1%
Hikma Pharmaceuticals's revenue per employee for the last fiscal year averaged $0.4M, while opex per employee averaged $0.1M for the same period.
Over next 12 months, Hikma Pharmaceuticals's ratio of sales and marketing spend to revenue is estimated to be XXX , while its R&D spend to revenue to be XXX .
Analysts estimate Hikma Pharmaceuticals's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See operational valuation multiples for Hikma Pharmaceuticals and other 10K+ public comps| FY 2024 | NTM | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|---|
| Revenue Growth | 9% | XXX | XXX | XXX | XXX |
| EBITDA Margin | 23% | XXX | XXX | XXX | XXX |
| EBITDA Growth | 32% | XXX | XXX | XXX | XXX |
| Rule of 40 (SaaS-only) | 25% | XXX | XXX | XXX | XXX |
| Revenue per Employee | $0.4M | XXX | XXX | XXX | XXX |
| Opex per Employee | $0.1M | XXX | XXX | XXX | XXX |
| S&M Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| G&A Expenses to Revenue | 18% | XXX | XXX | XXX | XXX |
| R&D Expenses to Revenue | 5% | XXX | XXX | XXX | XXX |
| Opex to Revenue | 26% | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Armata Pharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Hikma Pharmaceuticals acquired XXX companies to date.
Last acquisition by Hikma Pharmaceuticals was XXXXXXXX, XXXXX XXXXX XXXXXX . Hikma Pharmaceuticals acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Sign Up| When was Hikma Pharmaceuticals founded? | Hikma Pharmaceuticals was founded in 2005. |
| Where is Hikma Pharmaceuticals headquartered? | Hikma Pharmaceuticals is headquartered in United Kingdom of Great Britain and Northern Ireland. |
| How many employees does Hikma Pharmaceuticals have? | As of today, Hikma Pharmaceuticals has 9.5K+ employees. |
| Who is the CEO of Hikma Pharmaceuticals? | Hikma Pharmaceuticals's CEO is Mr. Riad Mishlawi. |
| Is Hikma Pharmaceuticals publicy listed? | Yes, Hikma Pharmaceuticals is a public company listed on LON. |
| What is the stock symbol of Hikma Pharmaceuticals? | Hikma Pharmaceuticals trades under HIK ticker. |
| When did Hikma Pharmaceuticals go public? | Hikma Pharmaceuticals went public in 2005. |
| Who are competitors of Hikma Pharmaceuticals? | Similar companies to Hikma Pharmaceuticals include e.g. Julphar, Galapagos, Pharming, Vivoryon Therapeutics. |
| What is the current market cap of Hikma Pharmaceuticals? | Hikma Pharmaceuticals's current market cap is $5.2B |
| What is the current revenue of Hikma Pharmaceuticals? | Hikma Pharmaceuticals's last 12-month revenue is $2.5B. |
| What is the current EBITDA of Hikma Pharmaceuticals? | Hikma Pharmaceuticals's last 12-month EBITDA is $650M. |
| What is the current EV/Revenue multiple of Hikma Pharmaceuticals? | Current revenue multiple of Hikma Pharmaceuticals is 2.0x. |
| What is the current EV/EBITDA multiple of Hikma Pharmaceuticals? | Current EBITDA multiple of Hikma Pharmaceuticals is 7.5x. |
| What is the current revenue growth of Hikma Pharmaceuticals? | Hikma Pharmaceuticals revenue growth between 2023 and 2024 was 9%. |
| Is Hikma Pharmaceuticals profitable? | Yes, Hikma Pharmaceuticals is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
